New T-Cell Treatment for CD4 Positive T-Cell Cancers
CD4 Redirected Chimeric Antigen Receptor T Cell Therapy for CD4 Positive T Cell Neoplasms
This clinical trial is exploring a new type of T-cell treatment for people with certain CD4 positive T-cell cancers that have not responded to previous therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11162445 on NIH RePORTER |
What this research studies
This is a first-in-human clinical trial to test a new approach called CD4 Redirected Chimeric Antigen Receptor T Cell Therapy, or CD4CAR. We will take a patient's own T-cells, modify them in the lab to specifically target and fight CD4 positive cancer cells, and then give them back to the patient. Before receiving these modified cells, patients will undergo a short course of chemotherapy to prepare their body. The main goal is to determine if this new treatment is safe and can be successfully manufactured for patients with relapsed or refractory CD4 positive T-cell lymphoma and leukemia.
Who could benefit from this research
Good fit: Ideal candidates are patients with CD4 positive T-cell lymphoma or leukemia that has returned or not responded to at least one prior standard therapy.
Not a fit: Patients whose cancer is not CD4 positive or who have not received prior standard therapy may not benefit from this specific approach.
Why it matters
Potential benefit: If successful, this new T-cell treatment could offer a new option for patients with CD4 positive T-cell cancers that have run out of other treatment choices.
How similar studies have performed: This is a "first-in-man" Phase I clinical trial, meaning this specific CD4CAR T-cell therapy is novel and has not been tested in humans before.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Salman, Huda — Indiana University Indianapolis
- Study coordinator: Salman, Huda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.